Patient no. | Age (years) | Sex | Stage of lymphoma | Indolent aggressive (0-1) | Baseline | At diagnosis of HBV reactivation | Time of diagnosis of HBV Reactivation | Time to HBV recovery | Nuc therapy duration | Follow up HBsAg status | Outcome | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HBs-Ag | HBV- DNA (UI/μL) | ALT (U/L) | Rituximab (yes/no) | Therapy | HBV- DNA (UI/μL) | Peak ALT (XN.V.) | Weeks after NHL therapy | Weeks after NUC start | Weeks | Pos/neg | ||||||
1 | 50 | F | IV | 1 | - | 0 | 23 | y | CHOP-R | 350.000 | 4,5x | 40 | 4 | 28 | Neg | Alive (NHL remission) |
2 | 73 | M | IV | 0 | - | 0 | 26 | n | VNCOP-B | 450.000 | 10x | 24 | 8 | Ongoing | Neg | Alive (NHL relapse) |
3 | 64 | F | I | 1 | - | 0 | 34 | y | Fludara-R | 650.000 | 12x | 12 | 4 | 22 | Neg | Alive (NHL remission) |
4 | 62 | M | 1 | - | 0 | 22 | y | CHOP-R | 130.000 | 4x | 44 | 3 | Ongoing | Pos | Alive (NHL relapse) | |
5 | 50 | F | II | 1 | - | 0 | 28 | y | CHOP-R | 910.000 | 20x | 20 | 8 | 44 | Neg | Alive (NHL remission) |
6 | 71 | M | IV | 0 | - | 0 | 19 | n | CHOP | 160.000 | 11x | 24 | 6 | 48 | Neg | NHL related death |
7 | 66 | M | 0 | - | 0 | 36 | n | VNCOP-B | 170.000 | 3,7x | 20 | Ongoing | Pos | Alive | ||
8 | 70 | M | IV | 0 | - | 0 | 31 | y | Fludara Nova -R | 160.000 | 5,4x | 72 | Ongoing | Pos | Alive | |
9 | 52 | F | I | 0 | - | 0 | 29 | n | CHOP | 550.000 | 6,1x | 14 | 7 | 46 | Neg | Alive |
10 | 60 | M | IV | 0 | - | 0 | 34 | n | CEOP, Gem, VNCOP-B | 340.000 | 6x | Until death | Pos | NHL related death |